MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 150
- Registration Number
- NCT00504608
Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 181
- Registration Number
- NCT00463788
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Saizen® E-Device User Trial
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 20
- Registration Number
- NCT00450190
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT00442650
- Locations
- 🇨🇭
Merck Serono Medical Information Office, Geneva, Switzerland
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 180
- Registration Number
- NCT00441103
Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 302
- Registration Number
- NCT00439517
- Locations
- 🇹🇭
Research Site, Pathumwan, Thailand
🇧🇷Research site, Cep Sao Paulo-SP, Brazil
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 517
- Registration Number
- NCT00404352
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization
Terminated
- Conditions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 294
- Registration Number
- NCT00402818
- Locations
- 🇨🇦
Medical Information - Canada, Mississauga, Ontario, Canada
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 460
- Registration Number
- NCT00367484
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 189
- Registration Number
- NCT00287118
- Locations
- 🇨🇭
Medical Information Switzerland, Geneva, Switzerland
© Copyright 2024. All Rights Reserved by MedPath